Association between heme oxygenase-1 promoter polymorphisms and the development of albuminuria in type 2 diabetes: A case-control study

Medicine (United States)

Volumn 94, Issue 43, 2015, Pages

  Lee, Eun Young ^a,b,c   Lee, Yong Ho ^c   Kim, Soo Hyun ^c   Chung, Kyu Sik ^c   Kwon, Obin ^c   Kim, Beom Seok ^c   Nam, Chung Mo ^c   Park, Chun Sik ^d   Lee, Byung Wan ^c   Kang, Eun Seok ^c   Cha, Bong Soo ^c   Lee, Hyun Chul ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLUCOSE; HEME OXYGENASE 1; HEMOGLOBIN A1C;

ADULT; ALBUMINURIA; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GLYCEMIC CONTROL; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COMPLICATION; GENETICS;

AGED; ALBUMINURIA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84946542683     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001825     Document Type: Article

References (34)

1. Kim JH, Kim DJ, Jang HC, et al. Epidemiology of micro-and macrovascular complications of type 2 diabetes in Korea. Diabetes Metab J. 2011;35:571-577.
2. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005;16:3736-3741.
3. Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab. 2015;30:147-158.
4. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy-a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96:1445-1454.
5. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int. 1996;50:2041-2046.
6. Hadjadj S, Tarnow L, Forsblom C, et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol. 2007;18:1284-1291.
7. Janssen B, Hohenadel D, Brinkkoetter P, et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes. 2005;54:2320-2327.
8. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444-452.
9. Abraham NG, Kappas A. Heme oxygenase and the cardiovascularrenal system. Free Radic Biol Med. 2005;39:1-25.
10. Courtney AE, Maxwell AP. Heme oxygenase 1: does it have a role in renal cytoprotection? Am J Kid Dis. 2008;51:678-690.
11. Exner M, Minar E, Wagner O, et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med. 2004;37:1097-1104.
12. Lavrovsky Y, Schwartzman ML, Levere RD, et al. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA. 1994;91:5987-5991.
13. Rueda B, Oliver J, Robledo G, et al. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis Rheum. 2007;56:3953-3958.
14. Chen Y, Chau L, Chen J, et al. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care. 2008;31:1615-1620.
15. Weimar W, Roodnat J, Ijzermans J, et al. Fundamental role for HO-1 in the self-protection of renal allografts. Am J Transplant. 2004;4:811-818.
16. Ono K, Goto Y, Takagi S, et al. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis. 2004;173:315-319.
17. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2013;36:S67-S74.
18. American Diabetes Association. (9) Microvascular Complications and Foot Care. Diabetes Care. 2015;38:S58-S66.
19. Han SJ, Kang ES, Kim HJ, et al. The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes. Mol Genet Metab. 2009;97:85-90.
20. Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens. 2003;21:1497-1503.
21. Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther. 2001;8:433-440.
22. Schillinger M, Exner M, Minar E, et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol. 2004;43:950-957.
23. Brezniceanu M, Liu F, Wei C, et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int. 2007;71:912-923.
24. Buis CI, van der Steege G, Visser DS, et al. Heme oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am J Transplant. 2008;8:377-385.
25. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconvertingenzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
26. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
27. Toda N, Takahashi T, Mizobuchi S, et al. Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. Crit Care Med. 2002;30:1512-1522.
28. Yoneya R, Nagashima Y, Sakaki K, et al. Hemolysate pretreatment ameliorates ischemic acute renal injury in rats. Nephron. 2002;92:407-413.
29. Exner M, Bñhmig GA, Schillinger M, et al. Donor heme oxygenase-1 genotype is associated with renal allograft function. Transplantation. 2004;77:538-542.
30. Courtney AE, McNamee PT, Middleton D, et al. Association of functional heme oxygenase-1 gene promoter polymorphism with renal transplantation outcomes. Am J Transplant. 2007;7:908-913.
31. Chin HJ, Cho HJ, Lee TW, et al. The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. J Korean Med Sci. 2009;24:S30-S37.
32. Courtney AE, McNamee PT, Heggarty S, et al. Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy. Nephrol Dial Transplant. 2008;23:608-611.
33. Chen Y-H, Lin S-J, Lin M-W, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet. 2002;111:1-8.
34. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol. 2007;36:166-174.